Keun Seok Lee

Ewha Womans University — South Korea

Medicine · Health Sciences

49h-index14.1kcitations340works3.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(131), Advanced Breast Cancer Therapies(90), Breast Cancer Treatment Studies(77), Monoclonal and Polyclonal Antibodies Research(74), Cancer Treatment and Pharmacology(73)

Publications335 total

Supplementary Table S1 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
2025Open Access
Supplementary Figure S3 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
2025Open Access
Supplementary Table S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
2025Open Access
Supplementary File 1 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
2025Open Access
Supplementary Figure S1 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
2025Open Access
Supplementary Figure S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
2025Open Access
Supplementary Table S4 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
2025Open Access
Zanidatamab in combination with docetaxel in first-line HER2-positive breast cancer: results from an open-label, multicenter, phase Ib/II study
ESMO Open·2025· 1 citedOpen Access
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy
npj Breast Cancer·2025Open Access
Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21)
ESMO Open·2025Open Access
ASO Author Reflections: Multimodal Sentinel Lymph Node Mapping in Breast Cancer: Efficacy and Clinical Implications After Neoadjuvant Chemotherapy
Annals of Surgical Oncology·2025
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)
BMC Cancer·2025Open Access
ASO Visual Abstract: Clinical Application of Multimodal Sentinel Lymph Node Mapping Method in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy: A Final Analysis
Annals of Surgical Oncology·2025
Development and pilot testing of a personalised decision aid for decision-making regarding fertility preservation in young female patients with cancer: a study protocol
BMJ Open·2025Open Access
Impact of a 24-Week Mobile App–Based Human Coaching Program on Body Composition and Lipid Metabolism in Breast Cancer Survivors With Overweight or Obesity: Single-Arm Prospective Cohort Study
JMIR mhealth and uhealth·2025Open Access
Clinical Application of Multimodal Sentinel Lymph Node-Mapping Method for Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy: A Final Analysis
Annals of Surgical Oncology·2025· 1 cited
Abstract PS17-10: Genomic and transcriptomic analyses of residual invasive triple-neg breast cancer after neoadjuvant chemotherapy in prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab + capecitabine versus capecitabine; KCSG-BR18-21)
Clinical Cancer Research·2025
Abstract P3-11-05: Three-year efficacy and safety of neoadjuvant chemotherapy with pertuzumab, atezolizumab, docetaxel, and trastuzumab in patients with stage II/III ERBB2-positive breast cancer (NeoPATH): a nonrandomized, multi-institutional, phase 2 trial
Clinical Cancer Research·2025
Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+ advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial.
Journal of Clinical Oncology·2025· 2 cited
Phase III of oral paclitaxel (DHP107) vs intravenous paclitaxel in HER2-negative recurrent or metastatic breast cancer (mBC): Primary analysis of a multinational optimal trial (NCT03315364).
Journal of Clinical Oncology·2025· 1 cited
page 1 of 17Next →

Frequent Co-authors

Jungsil Ro(22), In Hae Park(17), Joohyuk Sohn(14), Seock‐Ah Im(13), Youngmee Kwon(11), So‐Youn Jung(10), Young Ho Yun(9), Eun Sook Lee(9), Han Sung Kang(9), Sung‐Bae Kim(8), Kyung Hae Jung(8), Seeyoun Lee(8), Yeon Hee Park(7), Byung‐Ho Nam(7), Seok Won Kim(7), Kyu Eun Lee(6), Kyung Hwan Shin(6), Junji Tsurutani(5), Cristina Saura(5), Javier Cortés(5)